Michael Thomas Heffernan, Director at Trevi Therapeutics, Inc. (TRVI), bought 6,351 shares at $10.00 ($25K) on 2019-05-09, disclosed to the SEC on 2019-05-13.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 3,851 | $0 | 0.0% |
| 2 | $10.00 | 2,500 | $25K | 100.0% |
| Total | $3.94 avg | 6,351 | $25K | 100% |
| Filing → |
| COLL | SELL | 2022-12-14 | $8.4M | — | Filing → |
| COLL | SELL | 2021-03-17 | $2.5M | — | Filing → |
| COLL | SELL | 2020-08-12 | $500K | — | Filing → |